Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028522 · ClinicalTrials.gov registry record · Phase 1
R(+)XK469 in Treating Patients With Advanced Neuroblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT00028522: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00028522 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 85 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028522, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of R(+)XK469 in treating patients with advanced neuroblastoma. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.
Interventions
- DRUG R(+)XK469
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2001-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028522
The ClinicalTrials.gov registry entry for NCT00028522 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which R(+)XK469 is the first listed.
NCT00028522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028522 about?
NCT00028522 is a clinical study titled "R(+)XK469 in Treating Patients With Advanced Neuroblastoma". This phase I trial is studying the side effects and best dose of R(+)XK469 in treating patients with advanced neuroblastoma. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.
What is the current status of trial NCT00028522?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2001-12.
What interventions are being tested in trial NCT00028522?
The interventions under investigation include: R(+)XK469 (DRUG).
Who is sponsoring clinical trial NCT00028522?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.